DexCom shares closed up 6.6% following first quarter earnings, as results and management commentary highlighted outperformance in both revenue growth and key commercial execution, particularly across the underpenetrated type 2 diabetes population.

• Revenue grew 15% year-over-year (organic revenue +12%), driven by expanded global demand, new product launches, and active user base growth.
• U.S. growth was led by significant share gains among type 2 diabetes patients not using insulin, underpinned by increasing reimbursement and broadening clinical adoption.
• Recent commercial wins, including a new reimbursement agreement with Prime Therapeutics, are on track to expand U.S. commercial coverage for non-insulin type 2 patients to over 7 million lives by year-end.
• Management cited strong feedback and adoption trends for the new G7 15-day sensor system, which launched across all channels in the quarter and is receiving high marks for both wear time and enhanced accuracy.
• Forward pipeline includes expected near-term distribution of new patch technology (FDA cleared), expanded software offerings, and a forthcoming major randomized controlled trial readout at the ADA’s 2026 Scientific Sessions, further supporting the case for expanded payer coverage.